{
    "clinical_study": {
        "@rank": "75583", 
        "arm_group": [
            {
                "arm_group_label": "\"high\" dose LCPUFA", 
                "arm_group_type": "Experimental", 
                "description": "the \"high\" dose LCPUFA supplement is a drop that will be administered to ELBW infants."
            }, 
            {
                "arm_group_label": "\"low\" dose LCPUFA", 
                "arm_group_type": "Experimental", 
                "description": "the \"low\" dose LCPUFA supplement is a drop that will be administered to ELBW infants."
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "the \"placebo\" is a drop that will be administered to ELBW infants."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if buccal administration of a concentrated\n      formulation of long-chain polyunsaturated fatty acids (LCPUFA) can help to maintain\n      docosahexaenoic acid (DHA) levels in extremely low birth weight (ELBW) infants."
        }, 
        "brief_title": "PUFA Supplementation in Premature Infants", 
        "condition": [
            "Premature, Extremely Low Birth Weight Infants", 
            "Polyunsaturated Fatty Acid Levels"
        ], 
        "condition_browse": {
            "mesh_term": "Birth Weight"
        }, 
        "detailed_description": {
            "textblock": "This will be a multi-center, randomized, placebo controlled, double blind trial.\n\n      Two doses of PUFA will be compared to placebo- a \"high\" dose and a \"low\" dose.\n\n      ELBW infants will be enrolled into this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  a) Premature infant born at gestational age less than 34 weeks\n\n          -  b) Birth weight less than 1000 grams\n\n          -  c) Legally authorized representative is able to provide written informed consent\n             within the first 72 hours of life, prior to the performance of an protocol-specified\n             evaluations or procedures\n\n        Exclusion Criteria:\n\n          -  a) infants with known metabolic disorder\n\n          -  b) infants with known congenital gastrointestinal anomaly\n\n          -  c) infants who are deemed to be inappropriate for enrollment per attending\n             neonatologist"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "72 Hours", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01955044", 
            "org_study_id": "MJN 8662"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "\"high\" dose LCPUFA", 
                    "\"low\" dose LCPUFA"
                ], 
                "intervention_name": "LCPUFA supplement", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "PUFA supplement"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "neonatal prematurity", 
            "infant, extremely low birth weight", 
            "fatty acids, polyunsaturated"
        ], 
        "lastchanged_date": "January 8, 2014", 
        "location": [
            {
                "contact": {
                    "email": "dtrobinson@luriechildrens.org", 
                    "last_name": "Daniel T Robinson, MD", 
                    "phone": "312-227-4190"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Lurie Children's Hospital of Chicago"
                }, 
                "investigator": {
                    "last_name": "Daniel T Robinson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Daniel T Robinson, MD", 
                    "phone": "312-227-4190"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Prentice Women's Hospital"
                }, 
                "investigator": {
                    "last_name": "Daniel T Robinson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bfrost@northshore.org", 
                    "last_name": "Brandy L Frost, MD", 
                    "phone": "847-570-2033"
                }, 
                "facility": {
                    "address": {
                        "city": "Evanston", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60201"
                    }, 
                    "name": "NorthShore University HealthSystem"
                }, 
                "investigator": {
                    "last_name": "Brandy L Frost, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Early DHA Supplementation in Extremely Low Birth Weight Infants", 
        "overall_contact": {
            "email": "bfrost@northshore.org", 
            "last_name": "Brandy L Frost, MD", 
            "phone": "847-570-2033"
        }, 
        "overall_contact_backup": {
            "last_name": "Michael S Caplan, MD", 
            "phone": "847-570-2530"
        }, 
        "overall_official": {
            "affiliation": "NorthShore University HealthSystem", 
            "last_name": "Michael S Caplan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "LCPUFA levels will be measured at 2 weeks of life.", 
            "measure": "long-chain polyunsaturated fatty acid (LCPUFA) levels", 
            "safety_issue": "No", 
            "time_frame": "2 weeks of life"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01955044"
        }, 
        "responsible_party": {
            "investigator_affiliation": "NorthShore University HealthSystem Research Institute", 
            "investigator_full_name": "Brandy Frost", 
            "investigator_title": "Attending Neonatologist, Clinician Educator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "LCPUFA levels will be measured at 8 weeks of life.", 
                "measure": "LCPUFA levels", 
                "safety_issue": "No", 
                "time_frame": "8 weeks of life"
            }, 
            {
                "description": "Resolvin, a metabolite of LCPUFA, will be measured at 8 weeks of life.", 
                "measure": "resolvin levels", 
                "safety_issue": "No", 
                "time_frame": "8 weeks of life"
            }, 
            {
                "description": "resolvin, a metabolite of LCPUFA, will be measured at 2 weeks of life.", 
                "measure": "resolvin levels", 
                "safety_issue": "No", 
                "time_frame": "2 weeks of life"
            }
        ], 
        "source": "NorthShore University HealthSystem Research Institute", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Ann & Robert H Lurie Children's Hospital of Chicago", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Feinberg School of Medicine, Northwestern University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Mead Johnson Nutrition", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "NorthShore University HealthSystem Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}